Split History
ETFs Holding CHRS »    CHRS Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Coherus BioSciences is a commercial-stage biotherapeutics company focused on the biosimilar and immuno-oncology market. Co.'s product, UDENYCA® (pegfilgrastim-cbqv) is a biosimilar to Neulasta®, a long-acting granulocyte-colony stimulating factor. Co.'s pre-commercial pipeline includes the following product candidates: Toripalimab, an anti-PD-1 antibody being developed in collaboration with Shanghai Junshi Biosciences, Co., Ltd.; a bevacizumab (Avastin) biosimilar candidate in collaboration with Innovent Biologics (Suzhou) Co., Ltd.; CHS-1420 (its adalimumab (Humira) biosimilar candidate); and a ranibizumab (Lucentis) biosimilar candidate in collaboration with Bioeq IP AG. According to our CHRS split history records, Coherus BioSciences has had 2 splits.
CHRS split history picture
Coherus BioSciences (CHRS) has 2 splits in our CHRS split history database. The first split for CHRS took place on December 01, 1986. This was a 3 for 2 split, meaning for each 2 shares of CHRS owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. CHRS's second split took place on December 08, 1992. This was a 2 for 1 split, meaning for each share of CHRS owned pre-split, the shareholder now owned 2 shares. For example, a 1500 share position pre-split, became a 3000 share position following the split.

When a company such as Coherus BioSciences splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the CHRS split history from start to finish, an original position size of 1000 shares would have turned into 3000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Coherus BioSciences shares, starting with a $10,000 purchase of CHRS, presented on a split-history-adjusted basis factoring in the complete CHRS split history. CHRS split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/14/2011
End date: 04/13/2021
Start price/share: $4.43
End price/share: $13.92
Dividends collected/share: $0.00
Total return: 214.22%
Average Annual Total Return: 12.12%
Starting investment: $10,000.00
Ending investment: $31,412.55
Years: 10.01
Date Ratio
12/01/19863 for 2
12/08/19922 for 1
CHRS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CLBS Split History
CLDN Split History
CLDX Split History
CLRB Split History
CLRBW Split History
CLSN Split History
CMD Split History
CMN Split History
CNC Split History
CNDO Split History

Also explore: CHRS shares outstanding history

Aviat Networks, Inc. (AVNW)
Guardion Health Sciences, Inc. (GHSI)
China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
MicroSectors FANG+ Index 2X Leveraged ETNs due January 8, 2038 (FNGO)
MicroSectors FANG+ Index 3X Leveraged ETNs due January 8, 2038 (FNGU)
Moleculin Biotech, Inc. (MBRX)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CHRS Insider Buying

CHRS Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.